Form 4: Rigel Pharmaceuticals EVP Acquires 10,000 Shares Through Stock Option Award

Dean L. Schorno, EVP & Chief Financial Officer of Rigel Pharmaceuticals, acquired 10,000 shares of common stock through a stock option award after a performance metric was met.

Summary

• Dean L. Schorno, the EVP & Chief Financial Officer of Rigel Pharmaceuticals, acquired 10,000 shares of the company's common stock.
• This acquisition occurred through a stock option granted on February 6, 2020, with an exercise price of $24.20 per share, adjusted for a one-for-ten reverse stock split effective June 27, 2024.
• The stock option had a performance-based vesting condition that was satisfied on August 30, 2024, making the grant reportable under Section 16.
• The option was fully vested on August 30, 2024, when the performance metric was determined to have been met.
• Schorno now directly owns 10,000 derivative securities.

Sentiment

Score: 6

Explanation: The document indicates that a performance metric was met, leading to the vesting of stock options. This suggests positive performance, but it's a routine filing, so the sentiment is moderately positive.

Positives

• The vesting of the stock option suggests that performance metrics were achieved, which could be viewed positively.

Industry Context

Executive compensation through stock options is a common practice in the pharmaceutical industry to align management's interests with those of shareholders. The vesting of these options is often tied to performance metrics, incentivizing executives to achieve specific goals.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the pharmaceutical industry.
• Companies like Amgen, Gilead Sciences, and Vertex Pharmaceuticals also utilize stock options as part of their executive compensation plans.
• The vesting conditions and exercise prices are typically benchmarked against industry peers to ensure competitiveness and alignment with company performance.

Stakeholder Impact

• The vesting of stock options aligns the executive's interests with those of shareholders, potentially driving value creation.

Key Dates